Request Demo
Last update 20 Mar 2025
Peptide-based blood coagulant(Haemostatix Ltd.)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Recombinant protein |
Synonyms Haemostasis therapeutic, Haemostat topical, PeproStat + [2] |
Target |
Action stimulants |
Mechanism fibrin stimulants(Fibrin stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Peptide-based blood coagulant(Haemostatix Ltd.)NCT03131336
A Controlled, Randomized, Multi-centre, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis
EUCTR2016-003661-26-GB
A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStat in intraoperative surgical haemostasis - CLOTFAST 2
NCT02204930
A Multi-centre, Open-label, Uncontrolled, First-in-Human Study to Evaluate the Safety and Tolerability and Explore the Efficacy of PeproStat in Gelita-Spon® Gelatin Sponge in Subjects Undergoing Open Liver Resection Surgery
100 Clinical Results associated with Peptide-based blood coagulant(Haemostatix Ltd.)
Login to view more data
100 Translational Medicine associated with Peptide-based blood coagulant(Haemostatix Ltd.)
Login to view more data
100 Patents (Medical) associated with Peptide-based blood coagulant(Haemostatix Ltd.)
Login to view more data
100 Deals associated with Peptide-based blood coagulant(Haemostatix Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Blood Coagulation Disorders | Phase 2 | United Kingdom | 31 Mar 2017 | |
| Blood Coagulation Disorders | Phase 2 | Bosnia and Herzegovina | 31 Mar 2017 | |
| Blood Coagulation Disorders | Phase 2 | Croatia | 31 Mar 2017 | |
| Blood Coagulation Disorders | Phase 2 | Serbia | 31 Mar 2017 | |
| Blood Coagulation Disorders | Phase 2 | Poland | 31 Mar 2017 | |
| Hemorrhage | Phase 2 | Serbia | 31 Mar 2017 | |
| Hemorrhage | Phase 2 | Bosnia and Herzegovina | 31 Mar 2017 | |
| Hemorrhage | Phase 2 | Poland | 31 Mar 2017 | |
| Hemorrhage | Phase 2 | United Kingdom | 31 Mar 2017 | |
| Hemorrhage | Phase 2 | Croatia | 31 Mar 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 21 | xubjbpgmlm(ndigdncoji) = tdqicrvndl bwcekucxmb (rybdaeukxq ) | - | 20 May 2011 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free